Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 01, 2015 4:49 PM ET

Biotechnology

Company Overview of Apexigen Inc.

Company Overview

Apexigen Inc. operates as a biopharmaceutical product development company. It focuses on the development of product candidates for life-threatening and difficult to treat diseases. The company’s products include humanized antibodies for cancer, inflammatory diseases, and ophthalmic diseases. It discovers and develops rabbit-derived humanized monoclonal antibodies. The company was founded in 2010 and is based in Burlingame, California.

863 Mitten Road

Suite 103

Burlingame, CA 94010-1303

United States

Founded in 2010

Phone:

650-931-6236

Fax:

650-931-6235

Key Executives for Apexigen Inc.

Chief Executive Officer, President and Director
Vice President of Finance
Vice President of Business Development
Director of Preclinical Development and Clinical Research
Vice President of Clinical Development
Compensation as of Fiscal Year 2015.

Apexigen Inc. Key Developments

Apexigen, Inc. Announces the Initiation of A Phase 1 Clinical Trial of APX005M

Apexigen Inc. announced the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program. APX005M is an immuno-activating monoclonal antibody targeting CD40, a receptor that plays a central role in the regulation of antigen presentation functions and tumor-specific T cell response. The trial is a Phase 1, open-label dose-escalation study of APX005M in adults with solid tumors that is intended to establish the maximum tolerated dose, the pharmacokinetic profile and the overall safety and tolerability of APX005M. The study will also seek evidence of activation of the immune system in response to treatment and preliminary assessment of clinical response.

Apexigen, Inc. Appoints Ovid C. Trifan as Vice President, Clinical Development and Amy Wong as Vice President, Finance

Apexigen Inc. announced the appointments of Ovid C. Trifan, MD, PhD as Vice President, Clinical Development and Amy Wong as Vice President, Finance. Dr. Trifan previously held the position of Senior Medical Director in the Clinical Science group at Onyx Pharmaceuticals. Ms. Wong previously held the position of Vice President, Finance, Human Resources and Operations at Tobi.com.

Apexigen Inc. Presents at 2013 BIO Convention in China, Nov-12-2013 04:00 PM

Apexigen Inc. Presents at 2013 BIO Convention in China, Nov-12-2013 04:00 PM. Venue: China National Convention Center, No.7 Tianchen East Road, Chaoyang District, Beijing 100105, China.

Similar Private Companies By Industry

Company Name Region
Biotech Support Group Inc United States
Vetica Labs, Inc. United States
Taconic Biosciences, Inc. United States
Xcell Biosciences, Inc. United States
Human Longevity, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Apexigen Inc., please visit www.apexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.